Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,738,220
  • Shares Outstanding, K 149,033
  • Annual Sales, $ 13,445 M
  • Annual Income, $ 4,001 M
  • 60-Month Beta 0.41
  • Price/Sales 3.32
  • Price/Cash Flow 8.71
  • Price/Book 4.43
Trade BIIB with:

Options Overview

Details
  • Implied Volatility 44.22%
  • Historical Volatility 27.56%
  • IV Percentile 52%
  • IV Rank 14.65%
  • IV High 120.28% on 06/04/21
  • IV Low 31.16% on 08/12/21
  • Put/Call Vol Ratio 0.46
  • Today's Volume 4,856
  • Volume Avg (30-Day) 4,593
  • Put/Call OI Ratio 1.07
  • Today's Open Interest 58,541
  • Open Int (30-Day) 54,668

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 4.21
  • Number of Estimates 28
  • High Estimate 4.69
  • Low Estimate 3.65
  • Prior Year 8.84
  • Growth Rate Est. (year over year) -52.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
294.34 +1.41%
on 09/14/21
350.45 -14.83%
on 08/24/21
-43.25 (-12.66%)
since 08/20/21
3-Month
294.34 +1.41%
on 09/14/21
390.99 -23.66%
on 06/21/21
-89.95 (-23.16%)
since 06/18/21
52-Week
223.25 +33.70%
on 11/09/20
468.55 -36.29%
on 06/07/21
+24.01 (+8.75%)
since 09/18/20

Most Recent Stories

More News
Biogen Inc. (BIIB) Stock Moves -0.57%: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $298.49, marking a -0.57% move from the previous day.

BIIB : 298.49 (-0.57%)
Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion

The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.

REGN : 640.89 (-1.69%)
BIIB : 298.49 (-0.57%)
RHHBY : 45.5700 (-1.09%)
ALKS : 29.62 (-1.63%)
FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)

- BYOOVIZ(TM) becomes the first ophthalmology biosimilar to gain FDA approval in the United States

BIIB : 298.49 (-0.57%)
Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study

Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.

REGN : 640.89 (-1.69%)
BIIB : 298.49 (-0.57%)
VRTX : 185.67 (-1.40%)
RGEN : 306.05 (-0.28%)
CHMP Recommends VUMERITY(R) (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), issued a positive opinion and has recommended granting...

BIIB : 298.49 (-0.57%)
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy

BIIB : 298.49 (-0.57%)
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)

-- Clinical data available to date suggest there are remaining unmet needs in some spinal muscular atrophy (SMA) patients treated with Evrysdi

BIIB : 298.49 (-0.57%)
IONS : 36.19 (-2.74%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 76.17 (-1.98%)
BIIB : 298.49 (-0.57%)
ILMN : 438.00 (-2.02%)
IBB : 169.91 (-2.13%)
CTLT : 135.98 (-0.12%)
XBI : 128.76 (-3.10%)
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $295.95, marking a -1.98% move from the previous day.

BIIB : 298.49 (-0.57%)
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study

DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent...

BIIB : 298.49 (-0.57%)
PFE : 44.20 (+0.71%)
ABBV : 106.40 (-1.23%)
DMAC : 3.81 (-8.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

3rd Resistance Point 306.55
2nd Resistance Point 304.06
1st Resistance Point 301.28
Last Price 298.49
1st Support Level 296.01
2nd Support Level 293.52
3rd Support Level 290.74

See More

52-Week High 468.55
Fibonacci 61.8% 374.85
Fibonacci 50% 345.90
Fibonacci 38.2% 316.95
Last Price 298.49
52-Week Low 223.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar